THSP
PFE icon

Taube Hodson Stonex Partners’s Pfizer PFE Stock Holding History

Taube Hodson Stonex Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-4,303,944
Closed -$114M – 27
2013
Q2 		$114M Buy
+4,303,944
New +$119M 11.23% 1

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Taube Hodson Stonex Partners's PFE Position: Q3 2013 in Review

Taube Hodson Stonex Partners sold out of Pfizer (PFE) in Q3 2013, closing a stake of 4,303,944 shares — an estimated $114M sold.

Taube Hodson Stonex Partners first reported a position in PFE in Q2 2013 and held it in 1 quarter. The position peaked at $114M in Q2 2013. 1,606 funds tracked by Wall St. Rank hold PFE as of Q3 2013.

  • Taube Hodson Stonex Partners reported no remaining Pfizer position as of Q3 2013 after selling out during the quarter.
  • Taube Hodson Stonex Partners sold 4,303,944 Pfizer shares in Q3 2013, an estimated $114M.
  • Taube Hodson Stonex Partners first reported a position in Pfizer in Q2 2013 and held it in 1 quarter.
  • Taube Hodson Stonex Partners's Pfizer position peaked at $114M in Q2 2013.
  • 1,606 funds tracked by Wall St. Rank held Pfizer as of Q3 2013.

Based on Taube Hodson Stonex Partners's 13F filing for Q3 2013, filed 18 Oct 2013.